Aktuelle smitsomme sygdomme
Søgeord (rsv) valgt.
10 emner vises.
Medscape Infectious Diseases, 16.08.2024
Tilføjet 16.08.2024
Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and... Reuters Health Information
Læs mereMedscape Infectious Diseases, 13.08.2024
Tilføjet 13.08.2024
Correct timing for RSV testing and updated recommendations for three FDA-approved vaccines can reduce adult hospitalizations for this insidious infection. Medscape
Læs mereLea Gur-Arie, Michal Stein, Hanna Sefty, Ilana S Fratty, Ital Nemet, Limor Kliker, Nofar Atari, Neta S Zuckerman, Alina Rosenberg, Heftziba Ivgi, Orit Golan-Shany, Nadav Sorek, Orna Schwartz-Harari, Michal Bromberg, Lital Keinan-Boker, Michal Mandelboim, Aharona Glatman-Freedman and on behalf of the Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN)
Eurosurveillance latest updates, 9.08.2024
Tilføjet 9.08.2024
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic. AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework. MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework. ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives. ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 8.08.2024
Tilføjet 8.08.2024
This report describes ACIP recommendations for the use of the RSV vaccine for older adults.
Læs mereEduardo Azziz-Baumgartner, Avital Hirsch, Young M Yoo, Alon Peretz, David Greenberg, Yonat Shemer Avni, Aharona Glatman-Freedman, Michal Mandelboim, Adam MacNeil, Emily T Martin, Gabriella Newes-Adeyi, Mark Thompson, Arnold S Monto, Ran D Balicer, Min Z Levine and Mark A Katz
Eurosurveillance latest updates, 2.08.2024
Tilføjet 2.08.2024
BackgroundHealthcare personnel (HCP) are at high risk for respiratory infections through occupational exposure to respiratory viruses. AimWe used data from a prospective influenza vaccine effectiveness study in HCP to quantify the incidence of acute respiratory infections (ARI) and their associated presenteeism and absenteeism. MethodsAt the start and end of each season, HCP at two Israeli hospitals provided serum to screen for antibodies to influenza virus using the haemagglutination inhibition assay. During the season, active monitoring for the development of ARI symptoms was conducted twice a week by RT-PCR testing of nasal swabs for influenza and respiratory syncytial virus (RSV). Workplace presenteeism and absenteeism were documented. We calculated incidences of influenza- and RSV-associated ARI and applied sampling weights to make estimates representative of the source population. ResultsThe median age of 2,505 participating HCP was 41 years, and 70% were female. Incidence was 9.1 per 100 person-seasons (95% CI: 5.8–14.2) for RT-PCR-confirmed influenza and 2.5 per 100 person-seasons (95% CI: 0.9–7.1) for RSV illness. Each season, 18–23% of unvaccinated and influenza-negative HCP seroconverted. The incidence of seroconversion or RT-PCR-confirmed influenza was 27.5 per 100 person-seasons (95% CI: 17.8–42.5). Work during illness occurred in 92% (95% CI: 91–93) of ARI episodes, absence from work in 38% (95% CI: 36–40). ConclusionInfluenza virus and RSV infections and associated presenteeism and absenteeism were common among HCP. Improving vaccination uptake among HCP, infection control, and encouraging sick HCP to stay home are important strategies to reduce ARI incidence and decrease the risk of in-hospital transmission.
Læs mereECDC
ECDC COVID-19 updates, 29.07.2024
Tilføjet 29.07.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mereMedscape Infectious Diseases, 24.07.2024
Tilføjet 24.07.2024
Merck\'s antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV),... Reuters Health Information
Læs mereMedscape Infectious Diseases, 12.07.2024
Tilføjet 12.07.2024
Important changes to vaccination recommendations for COVID, flu, RSV, and pneumococcal disease -- and what\'s behind the changes -- are summarized here. Medscape Internal Medicine
Læs mereMedscape Infectious Diseases, 3.07.2024
Tilføjet 3.07.2024
The RSV season is peaking earlier and entailing higher rates of hospitalization, according to Canadian data. Medscape Medical News
Læs mereMedscape Infectious Diseases, 28.06.2024
Tilføjet 28.06.2024
Moderna\'s mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults. Medscape Medical News
Læs mere